Dynamics of AMR Spread, Persistence and Evolution Between Humans, Animals and Their Environment (Dyaspeo)

April 22, 2026 updated by: Assistance Publique - Hôpitaux de Paris
Humans in contact with animals such as dog owners, may be at risk of antimicrobial resistance (AMR) acquisition. This is the central issue to be investigated in DYASPEO

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Antimicrobial resistance (AMR) is a global and multifaceted public health problem. Advanced knowledge on AMR has demonstrated that it not only affects humans but is also widely distributed across animals and the environment. A major cause of the AMR burden refers to the capability of AMR to transmit within and between individuals, including between humans and animals. Leading examples of internationally distributed AMR bacteria are Enterobacterial disseminating resistances to extended-spectrum cephalosporins (ESC-E) and carbapenems (CP-E). Yet, the magnitude and pathways of their cross-sectorial transfers are poorly understood.

There is a great concern that humans in contact with animals be at risk of ESC-E/CP-E acquisition. Whereas an increase in ESC-E carriage in farmers in contact with their food-producing animals was reported, AMR transmission to humans through direct contacts with companion animals has been much less studied. Owing the close relationships between pets and owners, and the fact that 50% of households host a dog or a cat in France, the hypothesis of pet ownership being a risk for humans to acquire ESC-E/CP-E appears strongly relevant. The DYASPEO project will investigate this question through a combination of several approaches from field to laboratory studies, and including epidemiology, ecology, molecular and population genomics, studies on intestinal microbiota, modelling and social sciences.

We hypothesize that the interface between humans and companion animals plays a significant role in the transfer of ESC-E/CP-E. This hypothesis is corroborated (i) by recent data in France showing that antibiotic exposure of companion animals is still increasing contrary to all other animal host (e.g. food-producing animals) and (ii) by a recent study from the consortium demonstrating a high AMR prevalence in dogs getting back home after hospitalization.

Study Type

Observational

Enrollment (Estimated)

525

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • France
      • Maisons-Alfort, France, 94700
        • Recruiting
        • the National Veterinary School Alfort
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

The healthy volunteers (dog owners) will be recruited at a single recruitment centre, which is the National Veterinary School (Maisons-Alfort).

Description

Inclusion Criteria:

  • Adult or child planning to live in the same household as his/her dog during the three months following inclusion.
  • Planning to live in the same habitat in the next three months following inclusion (except for holidays).
  • Written consent of all adults and of at least one of the two parents for minors under parental authority. A different information note will be elaborated for each age category (6-10 yr-old, 10-15 yr-old and 16-18 yr-old).
  • Owning a dog recorded for a surgery at the National Veterinary School

Exclusion Criteria:

  • Lack of signed informed consent
  • Subject in alternating custody
  • Subject under legal protection (guardianship)
  • Subject deprived of liberty under judicial constraint
  • Subject undergoing psychiatric care
  • Lack of affiliation to a social security scheme
  • Volunteers who do not speak/write French

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
household
House Members (adults and minors) from 175 households owning a dog
Other: human faecal collection
collecting stools 6 times over a 90 days period and complete a questionnaire at the same times: D1, D7, D15, D30, D60 and D90
Other: ancillary study
interviews and/or ethnographic observations for 50 volunteers

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
generation of a list of priorities for future prevention and control strategies to mitigate antimicrobial resistance (AMR) transmission between companion animals and humans
Time Frame: over the 90 days follow up
mathematical models combining all the data (epidemiological, bacteriological, genomic, sociological) gathered in the project
over the 90 days follow up

Secondary Outcome Measures

Outcome Measure
Time Frame
Rates of AMR acquisitions in one or several housekeepers
Time Frame: over the 90 days follow up
over the 90 days follow up
A list in nature of changes in dog microbiota
Time Frame: over the 90 days follow up
over the 90 days follow up
A list in magnitude of changes in dog microbiota
Time Frame: over the 90 days follow up
over the 90 days follow up
A list in nature of changes in housekeepers microbiota
Time Frame: over the 90 days follow up
over the 90 days follow up
A list in magnitude of changes in housekeepers microbiota
Time Frame: over the 90 days follow up
over the 90 days follow up
explore unknown parameters of AMR colonization in dogs under various antibiotic exposures
Time Frame: over the 90 days follow up
over the 90 days follow up
the generation of a list of sociological factors and potential at-risk practices relevant in the transmission of AMR from dogs to housekeepers
Time Frame: during semi-directive interviews and/or observational periods
during semi-directive interviews and/or observational periods

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Assistance Publique - Hôpitaux de Paris

Investigators

  • Principal Investigator: Jean-Yves Madec, PHD, ANSES

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 15, 2025

Primary Completion (Estimated)

September 1, 2028

Study Completion (Estimated)

March 1, 2029

Study Registration Dates

First Submitted

February 8, 2024

First Submitted That Met QC Criteria

February 8, 2024

First Posted (Actual)

February 15, 2024

Study Record Updates

Last Update Posted (Actual)

April 23, 2026

Last Update Submitted That Met QC Criteria

April 22, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • APHP220101
  • 2023-A02282-43 (Other Identifier: IDRCB)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Antibiotic Resistant Strain

Clinical Trials on human faecal collection

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Czech Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe